Last reviewed · How we verify

AceLink Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

AceLink Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADvantage Therapeutics · 1 shared drug class
  2. AJU Pharm Co., Ltd. · 1 shared drug class
  3. AO GENERIUM · 1 shared drug class
  4. Abbott · 1 shared drug class
  5. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  6. Aciex Therapeutics, Inc. · 1 shared drug class
  7. Addpharma Inc. · 1 shared drug class
  8. 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AceLink Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). AceLink Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acelink-therapeutics-inc. Accessed 2026-05-17.

Related